USANA Health Sciences (NYSE:USNA) Cut to Strong Sell at Zacks Research

Key Points

• Zacks Research downgraded USANA Health Sciences from “hold” to “strong sell.” MarketBeat says the stock’s average analyst rating is “sell,” with two analysts assigning sell ratings.
• USANA’s latest quarter missed expectations, reporting a loss of $0.11 per share versus forecast earnings of $0.11, and revenue of $205.9 million versus an estimated $217.4 million.
• The company lowered its FY2026 outlook, projecting net sales near $900 million and adjusted EBITDA of about $77 million, signaling weaker near-term performance.

USANA Health Sciences (NYSE:USNA - Get Free Report) was downgraded by research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report released on Wednesday, Zacks reports.

A number of other research analysts also recently weighed in on USNA. Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Two investment analysts have rated the stock with a Sell rating. According to MarketBeat, the company currently has an average rating of "Sell".

USANA Health Sciences Trading Down 3.3%

Shares of USNA stock opened at $13.86 on Wednesday. The stock has a 50 day moving average of $14.61 and a 200 day moving average of $17.99. The stock has a market cap of $256.05 million, a P/E ratio of -12.05, a P/E/G ratio of 2.17 and a beta of 0.66. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $23.59.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.22). The firm had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million. USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%. On average, research analysts predict that USANA Health Sciences will post 0.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of USANA Health Sciences during the 2nd quarter worth about $33,182,000. Pzena Investment Management LLC acquired a new stake in USANA Health Sciences in the 2nd quarter worth about $25,739,000. Empowered Funds LLC purchased a new stake in USANA Health Sciences during the 2nd quarter worth approximately $1,500,000. Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences during the 2nd quarter worth approximately $17,295,080. Finally, Bank of New York Mellon Corp purchased a new stake in USANA Health Sciences during the 2nd quarter worth approximately $1,105,000. Hedge funds and other institutional investors own 54.25% of the company's stock.

Trending Headlines about USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.